L.J. Altfest & Co’s Biogen BIIB Stock Holding History

L.J. Altfest & Co’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,433	Closed	-$371K	–	311
2023 Q4	$371K	Buy	1,433 +174	+14%	+$42.7K	0.05%	226
2023 Q3	$324K	Buy	+1,259	New	+$337K	0.05%	227

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

L.J. Altfest & Co's BIIB Position: Q1 2024 in Review

L.J. Altfest & Co sold out of Biogen (BIIB) in Q1 2024, closing a stake of 1,433 shares — an estimated $371K sold.

L.J. Altfest & Co first reported a position in BIIB in Q3 2023 and held it in 2 quarters. The position peaked at $371K in Q4 2023. 954 funds tracked by Wall St. Rank hold BIIB as of Q1 2024.

L.J. Altfest & Co reported no remaining Biogen position as of Q1 2024 after selling out during the quarter.
L.J. Altfest & Co sold 1,433 Biogen shares in Q1 2024, an estimated $371K.
L.J. Altfest & Co first reported a position in Biogen in Q3 2023 and held it in 2 quarters.
L.J. Altfest & Co's Biogen position peaked at $371K in Q4 2023.
954 funds tracked by Wall St. Rank held Biogen as of Q1 2024.

Based on L.J. Altfest & Co's 13F filing for Q1 2024, filed 22 Apr 2024.